BioMarin Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $119 at Deutsche Bank
August 3, 2017 8:52 AM EDTDeutsche Bank raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $119.00 (from $118.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Todays results and hemophilia update continue to support our bullish view on BioMarins diversified and high-growth portfolio. Second quarter... More
BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
August 2, 2017 4:27 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More